Literature DB >> 18004726

Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.

Aparna Gupta1, Yongqing Wang, Christopher Browne, Susan Kim, Tom Case, Manik Paul, Marcia L Wills, Robert J Matusik.   

Abstract

BACKGROUND: Neuroendocrine (NE) prostate cancer develops as an aggressive disease that does not respond to androgen ablation therapy. It has been demonstrated that the paracrine action of NE cells facilitates the progression of androgen dependent adenocarcinoma to an androgen independent state, suggesting a significant role for NE cells during failure of androgen ablation therapy.
METHODS: To investigate the pathways that are involved in NE differentiation of prostate cancer, we have looked at the expression of genes known to be involved in endocrine differentiation of beta-cells in the pancreas. This study has been performed using the NE prostate cancer mouse model (12T-10) and the derivative allograft model (NE-10).
RESULTS: Immunohistochemical studies have shown that the neuroendocrine prostate tumors express the transcription factors Foxa2, mouse achaete-scute homolog-1 (mash-1), neurogenin3 (Ngn3) and Nkx2.2. These tumors show a loss of hairy/enhancer of split (Hes-1), a gene that inhibits NE differentiation. Human NE prostate cancers also express Foxa2 and human achaete-scute homolog-1 (HASH-1). These genes are expressed in NE prostate tumors in the similar sequential manner as they appear in a pancreatic beta-cell endocrine differentiation. Foxa2 expression is detected in early prostatic intraepithelial neoplasia (PIN). Mash-1 expression is detected in a few clusters within low grade PIN lesions and Nkx2.2 expression is rarely detected in individual scattered cells within the PIN lesion. Ngn3 and Nkx2.2 frequently appear in the invasive NE cancer. Subsequent NE metastasis to lung and liver show a distinct gene expression pattern. The lung metastasis expresses Ngn3 but does not express Nkx2.2 whereas liver metastases do not express Ngn3 but express Nkx2.2.
CONCLUSIONS: These results suggest that Ngn3 and Nkx2.2 expression are markers for site-specific metastasis and/or transcriptionally regulated genes that are required for organ-specific metastasis. This study indicates that a pathway similar to pancreatic beta-cell differentiation is involved in NE differentiation of prostate cancer. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18004726     DOI: 10.1002/pros.20650

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  17 in total

Review 1.  Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy.

Authors:  Li Li; Ping Tang; Shun Li; Xiang Qin; Hong Yang; Chunhui Wu; Yiyao Liu
Journal:  Med Oncol       Date:  2017-09-16       Impact factor: 3.064

Review 2.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

3.  Two novel determinants of etoposide resistance in small cell lung cancer.

Authors:  Malcolm H Lawson; Natalie M Cummings; Doris M Rassl; Roslin Russell; James D Brenton; Robert C Rintoul; Gillian Murphy
Journal:  Cancer Res       Date:  2011-06-03       Impact factor: 12.701

4.  Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.

Authors:  Giovanna Danza; Claudia Di Serio; Fabiana Rosati; Giuseppe Lonetto; Niccolò Sturli; Doreen Kacer; Antonio Pennella; Giuseppina Ventimiglia; Riccardo Barucci; Annamaria Piscazzi; Igor Prudovsky; Matteo Landriscina; Niccolò Marchionni; Francesca Tarantini
Journal:  Mol Cancer Res       Date:  2011-12-15       Impact factor: 5.852

Review 5.  Cancer stem cells: a major culprit of intra-tumor heterogeneity.

Authors:  Faiza Naz; Mengran Shi; Salvia Sajid; Zhao Yang; Changyuan Yu
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

6.  Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics.

Authors:  Natalie P Archer; Virginia Perez-Andreu; Michael E Scheurer; Karen R Rabin; Erin C Peckham-Gregory; Sharon E Plon; Ryan C Zabriskie; Pedro A De Alarcon; Karen S Fernandez; Cesar R Najera; Jun J Yang; Federico Antillon-Klussmann; Philip J Lupo
Journal:  Cancer       Date:  2016-08-16       Impact factor: 6.860

Review 7.  Exploring the origins of the normal prostate and prostate cancer stem cell.

Authors:  Susan Kasper
Journal:  Stem Cell Rev       Date:  2008-09       Impact factor: 5.739

Review 8.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

9.  Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.

Authors:  Aparna Gupta; Xiuping Yu; Tom Case; Manik Paul; Michael M Shen; Klaus H Kaestner; Robert J Matusik
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

10.  NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM.

Authors:  Jihan K Osborne; Jill E Larsen; Misty D Shields; Joshua X Gonzales; David S Shames; Mitsuo Sato; Ashwinikumar Kulkarni; Ignacio I Wistuba; Luc Girard; John D Minna; Melanie H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.